Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in
certain subgroups of patients. To date, no treatment has been shown to be effective in
patients with early-onset disease and mild symptoms. Experimental studies have demonstrated a
potential anti-inflammatory role of Fluvoxamine, Metformin and Ivermectin in SARS-CoV-2
infections and observational studies have suggested a reduced complications in patients with
COVID-19 disease.
Phase:
Phase 3
Details
Lead Sponsor:
Cardresearch
Collaborators:
Cytel Inc. Eiger BioPharmaceuticals Fastgrants McMaster University RainWater Foundation